Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients
Abstract OncotypeDX and MammaPrint assays have not been validated to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in early-stage breast cancer patients. We analyzed the 2010–2019 National Cancer Database and found that high OncotypeDX recurrence scores or high MammaP...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-05-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-023-00536-z |